Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of 10x Genomics Inc (NASDAQ: TXG) closed at $27.94 in the last session, down -3.49% from day before closing price of $28.95. In other words, the price has decreased by -$3.49 from its previous closing price. On the day, 2.08 million shares were traded. TXG stock price reached its highest trading level at $29.45 during the session, while it also had its lowest trading level at $27.59.
Ratios:
We take a closer look at TXG’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.69. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on December 14, 2023, initiated with a Buy rating and assigned the stock a target price of $60.
On December 13, 2023, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $55.
BofA Securities Upgraded its Underperform to Neutral on December 12, 2023, whereas the target price for the stock was revised from $36 to $54.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Saxonov Serge sold 4,660 shares for $44.00 per share. The transaction valued at 205,021 led to the insider holds 842,900 shares of the business.
Saxonov Serge sold 2,821 shares of TXG for $130,737 on Feb 22 ’24. The Chief Executive Officer now owns 847,560 shares after completing the transaction at $46.34 per share. On Feb 22 ’24, another insider, Hindson Benjamin J., who serves as the insider of the company, sold 2,613 shares for $46.34 each. As a result, the insider received 121,098 and left with 283,059 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 3329526016 and an Enterprise Value of 3036188160. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.41 while its Price-to-Book (P/B) ratio in mrq is 4.49. Its current Enterprise Value per Revenue stands at 4.907 whereas that against EBITDA is -19.043.
Stock Price History:
Over the past 52 weeks, TXG has reached a high of $63.57, while it has fallen to a 52-week low of $26.75. The 50-Day Moving Average of the stock is -30.78%, while the 200-Day Moving Average is calculated to be -38.76%.
Shares Statistics:
According to the various share statistics, TXG traded on average about 1.40M shares per day over the past 3-months and 1738020 shares per day over the past 10 days. A total of 105.04M shares are outstanding, with a floating share count of 98.51M. Insiders hold about 17.70% of the company’s shares, while institutions hold 80.59% stake in the company. Shares short for TXG as of 1711584000 were 8518871 with a Short Ratio of 6.09, compared to 1709164800 on 6891767. Therefore, it implies a Short% of Shares Outstanding of 8518871 and a Short% of Float of 10.16.
Earnings Estimates
The stock of 10x Genomics Inc (TXG) is currently in the spotlight, with TBG analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $159.68, with high estimates of $27.94 and low estimates of $93.30.
